Drugs

, Volume 77, Issue 9, pp 1029–1034 | Cite as

Niraparib: First Global Approval

AdisInsight Report

Abstract

Oral niraparib, a highly-selective, potent poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor, is approved in the USA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. It is also under regulatory review in the EU for use in maintenance treatment in patients with platinum-sensitive, recurrent epithelial ovarian cancer who are in response to platinum-based chemotherapy. In the multinational, phase 3 NOVA trial in adult patients with platinum-sensitive, recurrent ovarian cancer, niraparib significantly prolonged median progression-free survival, irrespective of the presence or absence of a germline BRCA (gBRCA) mutation and irrespective of the presence or absence of homologous recombinant deficiency. Niraparib is also in development for use in other solid tumours, including breast and prostate cancer. This article summarizes the milestones in the development of niraparib leading to its first global approval for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

References

  1. 1.
    Jones P, Wilcoxen K, Rowley M, et al. Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. J Med Chem. 2015;58(8):3302–14.CrossRefPubMedGoogle Scholar
  2. 2.
    O’Sullivan Coyne G, Chen AP, Meehan R, et al. PARP inhibitors in reproductive system cancers: current use and developments. Drugs. 2017;77(2):113–30.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Tesaro. Tesaro announces expanded development program for niraparib focused on the treatment of front-line metastatic ovarian and lung cancer and metastatic breast cancer. 2017. http://www.tesarobio.com. Accessed 3 Apr 2017.
  4. 4.
    Tesaro. ZEJULA™ (Niraparib): US prescribing information. 2017. https://www.accessdata.fda.gov/. Accessed 29 Mar 2017.
  5. 5.
    European Medicines Agency. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use. 2016. http://www.ema.europa.eu. Accessed 3 Apr 2017.
  6. 6.
    Tesaro. Tesaro announces acceptance for review of niraparib marketing authorization by EMA. 2016. http://tesarobio.com. Accessed 3 Apr 2017.
  7. 7.
    Jones P, Altamura S, Boueres J, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009;52(22):7170–85.CrossRefPubMedGoogle Scholar
  8. 8.
    Bridges KA, Toniatti C, Buser CA, et al. Niraparib (MK-4827), a novel poly(ADP-ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 2014;5(13):5076–86.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Mueller S, Bhargava S, Molinaro AM, et al. Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer Res. 2013;33(3):755–62.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Wang L, Mason KA, Ang KK, et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012;30(6):2113–20.CrossRefPubMedGoogle Scholar
  11. 11.
    van Andel L, Zhang Z, Lu S, et al. Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Invest New Drugs. 2017. doi:10.1007/s10637-017-0451-2.Google Scholar
  12. 12.
    Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64.CrossRefPubMedGoogle Scholar
  13. 13.
    Gonzalez-Martin A, Backes FJ, Baumann KH, et al. A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy [abstract no. TPS5606]. J Clin Oncol. 2016;34(Suppl.).Google Scholar
  14. 14.
    Moore KN, Rimel B, Agarwal S, et al. A Phase 2, open label study of niraparib in women with advanced, relapsed, highgrade serous epithelial ovarian, fallopian tube or primary peritoneal cancer after 3 previous chemotherapy regimens [abstract no. TPS5609]. J Clin Oncol. 2015;33(Suppl. 1).Google Scholar
  15. 15.
    Balmana J, Tryfonidis K, Audeh W, et al. A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician’s choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study) [abstract no. OT1-03-05]. Cancer Res. 2016;76(4 Suppl. 1).Google Scholar
  16. 16.
    Mirza MR, Mortensen CE, DePont Christensen R, et al. A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: the ENGOT-OV24/AVANOVA1 trial [abstract no. 5555]. J Clin Oncol. 2016;34(Suppl.).Google Scholar
  17. 17.
    Mirza MR, Mortensen CE, Avall-Lundqvist E, et al. ENGOT-OV24-NSGO/AVANOVA: niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinumsensitive epithelial ovarian, fallopian tube, or peritoneal cancer [abstract no. TPS5607]. J Clin Oncol. 2015;33(Suppl. 1).Google Scholar
  18. 18.
    Konstantinopoulos P, Moore KN, Sachdev JC, et al. Phase I/II study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162) [abstract no. TPS5599]. J Clin Oncol. 2016;34(Suppl.).Google Scholar
  19. 19.
    Flores JP, Mathew P. Combination therapy with enzalutamide and the poly (ADPribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC): HCRN GU 14-202 [abstract no. TPS5095]. J Clin Oncol. 2016;34(Suppl.).Google Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations